Helsinn's (fosnetupitant + palonosetron) Receives FDA Approval for Managing Chemotherapy-Induced Nausea and Vomiting (CINV)
Shots:
- The approval is based on two clinical studies results assessing Akynzeo (NEPA) vs Palonosetron in patients with CINV across 80 centers in 11 countries
- The two clinical studies Trial 1 (NCT#02557035) & Trial 2 (NCT # 02517021) indicated benefits & side effect of Akynzeo in 440 & 404 patients respectively
- Akynzeo is a combination of (fosnetupitant 235mg- a P/neurokinin-1 (NK-1) receptor antagonists- & palonosetron 0.25mg- a serotonin-3 (5-HT3) receptor antagonist)- IV) used in combination with dexamethasone to prevent acute and delayed nausea & vomiting occurred during repetitive course of CT
Ref: Helsinn | Image: Twitter
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
